Memorial Sloan Kettering Cancer Center today launched a transformative initiative to improve the quality of cancer care and the lives of cancer patients. Hartford HealthCare, a multi-hospital health care system in Connecticut, was selected as a pioneering member of the newly formed Memorial Sloan Kettering Cancer Alliance.
For the first time, a genetic link specific to risk of childhood leukemia has been identified, according to a team of researchers from Memorial Sloan Kettering Cancer Center, St. Jude Children’s Research Hospital, University of Washington, and other institutions.
Memorial Sloan Kettering Cancer Center has announced the appointment of David R. Jones as Chief of the Thoracic Service in the Department of Surgery, and Charles M. Rudin as Chief of the Thoracic Oncology Service, Division of Solid Tumor Oncology, in the Department of Medicine.
A Memorial Sloan Kettering Cancer Center study shows that the use of MRI before or immediately after surgery in women with DCIS was not associated with reduced local recurrence or contralateral breast cancer rates.
Patients with advanced kidney cancer can now take advantage of a new treatment option that has far fewer troubling side effects – this, according to a large, international trial led by Memorial Sloan Kettering Cancer Center investigators.
A new study by thoracic surgeons and pathologists at Memorial Sloan Kettering Cancer Center shows that a specific pattern found in the tumor pathology of some lung cancer patients is a strong predictor of recurrence.
The combination of the immunotherapy drug ipilimumab and the investigational antibody drug nivolumab led to long-lasting tumor shrinkage in more than half of patients with metastatic melanoma, according to results from a Phase I trial simultaneously published in The New England Journal of Medicine and presented at the 49th Annual Meeting of the American Society of Clinical Oncology.